Trial · NCT01474772
Results by group72
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 72
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Average Diabetic Peripheral Neuropathy (DPN) Pain Based on a Numeric Rating Scale (NRS) Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period) | Pregabalin | 4.73 | Standard Error 0.14 | units on a scale | |
| Average Diabetic Peripheral Neuropathy (DPN) Pain Based on a Numeric Rating Scale (NRS) Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period) | Placebo | 4.96 | Standard Error 0.14 | units on a scale | |
| Average Weekly DPN Pain Based on a NRS (Baseline, 6 Weeks in Period 1, 2 Weeks Washout and 6 Weeks in Period 2) | Pregabalin | V6 (N: 101, 102) | 4.66 | Standard Deviation 1.77 | units on a scale |
| Average Weekly DPN Pain Based on a NRS (Baseline, 6 Weeks in Period 1, 2 Weeks Washout and 6 Weeks in Period 2) | Placebo | V6 (N: 101, 102) | 5.29 | Standard Deviation 1.93 | units on a scale |
| Average Weekly DPN Pain Based on a NRS (Baseline, 6 Weeks in Period 1, 2 Weeks Washout and 6 Weeks in Period 2) | Pregabalin | V11 (N: 97, 84) | 4.57 | Standard Deviation 2.22 | units on a scale |
| Average Weekly DPN Pain Based on a NRS (Baseline, 6 Weeks in Period 1, 2 Weeks Washout and 6 Weeks in Period 2) | Placebo | V11 (N: 97, 84) | 4.38 | Standard Deviation 2.17 | units on a scale |
| DPN Pain on Walking Based on a 11-point NRS of Each Treatment Period (Week 6 of Each Treatment Period) | Pregabalin | 4.28 | Standard Error 0.15 | units on a scale | |
| DPN Pain on Walking Based on a 11-point NRS of Each Treatment Period (Week 6 of Each Treatment Period) | Placebo | 4.41 | Standard Error 0.15 | units on a scale | |
| Percentage of Participants Achieving 30% Reduction in Mean DPN Pain Score From Baseline at the End of Each Treatment Period (Week 6 of Each Treatment Period) | Pregabalin | V6 (N: 101, 102) | 38.6 | percentage of participants | |
| Percentage of Participants Achieving 30% Reduction in Mean DPN Pain Score From Baseline at the End of Each Treatment Period (Week 6 of Each Treatment Period) | Placebo | V6 (N: 101, 102) | 24.5 | percentage of participants | |
| Percentage of Participants Achieving 30% Reduction in Mean DPN Pain Score From Baseline at the End of Each Treatment Period (Week 6 of Each Treatment Period) | Pregabalin | V11 (N: 97, 84) | 46.4 | percentage of participants | |
| Percentage of Participants Achieving 30% Reduction in Mean DPN Pain Score From Baseline at the End of Each Treatment Period (Week 6 of Each Treatment Period) | Placebo | V11 (N: 97, 84) | 47.6 | percentage of participants | |
| Percentage of Participants Achieving 50% Reduction in Mean DPN Pain Score From Baseline at the End of Each Treatment Period (Week 6 of Each Treatment Period) | Pregabalin | V6 (N: 101, 102) | 23.8 | percentage of participants | |
| Percentage of Participants Achieving 50% Reduction in Mean DPN Pain Score From Baseline at the End of Each Treatment Period (Week 6 of Each Treatment Period) | Placebo | V6 (N: 101, 102) | 13.7 | percentage of participants | |
| Percentage of Participants Achieving 50% Reduction in Mean DPN Pain Score From Baseline at the End of Each Treatment Period (Week 6 of Each Treatment Period) | Pregabalin | V11 (N: 97, 84) | 27.8 | percentage of participants | |
| Percentage of Participants Achieving 50% Reduction in Mean DPN Pain Score From Baseline at the End of Each Treatment Period (Week 6 of Each Treatment Period) | Placebo | V11 (N: 97, 84) | 32.1 | percentage of participants | |
| Brief Pain Inventory-Short Form (BPI-sf) Score for Pain-Severity Domain at the End of Each Treatment Period (Week 6 of Each Treatment Period) | Pregabalin | 16.76 | Standard Error 0.56 | units on a scale | |
| Brief Pain Inventory-Short Form (BPI-sf) Score for Pain-Severity Domain at the End of Each Treatment Period (Week 6 of Each Treatment Period) | Placebo | 17.56 | Standard Error 0.75 | units on a scale | |
| BPI-sf Score for Pain-Interference Domain at the End of Each Treatment Period (Week 6 of Each Treatment Period) | Pregabalin | 22.58 | Standard Error 0.96 | units on a scale | |
| BPI-sf Score for Pain-Interference Domain at the End of Each Treatment Period (Week 6 of Each Treatment Period) | Placebo | 23.75 | Standard Error 0.98 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01474772/results